Fintel on MSN2d
William Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform Recommendation
Fintel reports that on February 28, 2025, William Blair initiated coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a ...
William Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)
Equities researchers at William Blair started coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) in a research note issued to investors on Friday, Marketbeat reports. The firm ...
Terns Pharmaceuticals initiated with a Market Perform at William Blair
William Blair initiated coverage of Terns Pharmaceuticals (TERN) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy ...
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertiseFOSTER CITY, Calif., Feb. 20, ...
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
The Company granted Mr. Gengos a new hire option to purchase 750,000 shares of Terns common stock. The option has a 10-year term and an exercise price per share equal to $3.73, which was the closing ...
Nasdaq6d
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing small-molecule therapies for serious diseases, announced the appointment of Andrew Gengos as its new chief financial ...
Mena FN5d
Terns Pharmaceuticals Provides Program Updates And Announces Participation At TD Cowen 45Th Annual Healthcare Conference
(MENAFN- GlobeNewsWire - Nasdaq) TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ...
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule ...